COVID-19 - Daxor

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Optimal Volume Management is Key to Survivability

Oxygenation by the lungs and pumping of the heart carries
optimal blood volume to supply oxygen to vital organs.

Blood Volume Measurement Provides Actionable Information to Achieve Optimal Fluid Management

New data in journal Critical Care, N = 6

BVA identified true volume status vs. clinical exam in 6/6 patients

50% identified as hypovolemic/anemic

67% elevated albumin transudation rate

“Fluid resuscitation in COVID-19 patients could benefit from knowing the blood volume and capillary leak rate of patients as they are subject to significant leak and related hypovolemia.”

Yan Bakker, M.D.

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Blood Volume Measurements Improved Survival

Prospective randomized control trial in Surgical ICU

N=100, 70% Septic Shock / Sepsis / ARDS

66% reduction in mortality

20% reduction in LOS

36 hour earlier treatment decisions

44% change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

66% reduction in mortality

44% change in treatment strategy

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Capillary leak rate shown to be predictive of ICU mortality in cohort with 70% respiratory failure.

Rate at which the albumin transudates out of circulation shown to be predictive of ICU mortality in cohort with 70% respiratory failure.

Retrospective Study in Surgical ICU

N = 164

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

BVA Increases Ventilator Availability by Shortening Days on Ventilator

Adapted from CDC / Economist

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Knowledge of volume status avoids dangers of under and over resuscitation, ensuring fluid treatment interventions in accordance with measured volume derangements.

» A Protocol for Volume-Guided Therapy for Critical Care of COVID-19 Patients

“One of the mysteries of post-acute sequelae SARS-CoV-2 is the basis for non-specific, enduring, debilitating symptoms such as ‘brain fog’ executive dysfunction, exercise intolerance, and orthostatic intolerance. There are several potential mechanisms, including low blood volume.”

Dr. David S. Goldstein, M.D., Ph.D., National Institute of Neurological Disorders and Stroke

» Read How Blood Volume Analysis To Be Used As a Key Metric in NIH Study of “Long Hauler” COVID-19 Patients

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

Hypervolemia present in 48% control vs. 37% BVA

RBC deficiency present in 33% control vs. 16% BVA

Control group mean delay in transfusion of 1.5 ± 2 days

PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

FAQs

How does BVA help manage patients with Respiratory Distress, Sepsis/Septic Shock & ARDS?

BVA precisely measures total blood volume and red blood cell volume with 98% accuracy, guiding an effective, patient-specific fluid management strategy for optimal results.

What is the benefit of knowing the Albumin Transudation Slope?

Albumin Transudation Slope provides the rate at which the albumin transudates out of circulation through the capillary bed. A rate of approximately 0.25% per minute is considered normal. In a patient with increased capillary permeability, this rate may increase.

Is the BVA test FDA-cleared and available now?

The BVA test is FDA-cleared with over 45,000 tests used to date to assess blood volume in a network of hospitals across the U.S.

More FAQs

Key Resources

» A prospective randomized trial using blood volume analysis in addition to pulmonary artery catheter, compared with pulmonary artery catheter alone, to guide shock resuscitation in critically ill surgical patients.

» Blood Volume Analysis for COVID-19: A rapid blood test for precision resuscitation to reduce mortality in the ICU.

» A Protocol for Volume-Guided Therapy for Critical Care of COVID-19 Patients.

News & Events

25 MAY 2022

Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

5 JAN 2022

Daxor Announces Key Milestones Achieved for Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

4 AUG 2020

Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

19 NOV 2020

Third Hospital Joins Multicenter Covid-19 BVA-100® Blood Test Study

29 OCT 2020

Oregon Health & Science University Joins Multicenter Covid-19 BVA-100® Study

In the Spotlight

BioSpace:

Update on the Novel Coronavirus

MPO Magazine:

FDA-Cleared Blood Test Used to Guide COVID-19 Treatment

Technology Networks:

Maintaining Optimal Blood Volume in COVID-19 Patients

BioTuesdays:

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

MedGadget:

Blood Volume Analysis Using The BVA-100: Interview with Michael Feldschuh, Daxor CEO

Discover More

BioWorld:

Blood Volume Assessment Study to use Daxor Device

Discover More

In the Spotlight

BioSpace:

Update on the Novel Coronavirus

Discover More

MPO Magazine:

FDA-Cleared Blood Test Used to Guide COVID-19 Treatment

Discover More

Technology Networks:

Maintaining Optimal Blood Volume in COVID-19 Patients

Discover More

BioTuesdays:

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Discover More

MedGadget:

Blood Volume Analysis Using The BVA-100: Interview with Michael Feldschuh, Daxor CEO

Discover More

BioWorld:

Blood Volume Assessment Study to use Daxor Device

Discover More

View Our Story

Partner With the Dedicated Leader in BVA

As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.

Volume is Vital. End the Debate With Daxor.

Call us at 865-425-0555.

Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.

Daxor Corporation – 107 Meco Lane, Oak Ridge, TN 37830
Phone: 865-425-0555 | Fax: 865-425-0551
info@daxor.com | daxor.com

ISO 13485 Certified

Made in the USA.